Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California, USA.
Collaborative Mass Spectrometry Innovation Center, University of California San Diego, La Jolla, California, USA.
Clin Transl Sci. 2022 Mar;15(3):761-770. doi: 10.1111/cts.13198. Epub 2021 Nov 28.
Chemicals, including some systemically administered xenobiotics and their biotransformations, can be detected noninvasively using skin swabs and untargeted metabolomics analysis. We sought to understand the principal drivers that determine whether a drug taken orally or systemically is likely to be observed on the epidermis by using a random forest classifier to predict which drugs would be detected on the skin. A variety of molecular descriptors describing calculated properties of drugs, such as measures of volume, electronegativity, bond energy, and electrotopology, were used to train the classifier. The mean area under the receiver operating characteristic curve was 0.71 for predicting drug detection on the epidermis, and the SHapley Additive exPlanations (SHAP) model interpretation technique was used to determine the most relevant molecular descriptors. Based on the analysis of 2561 US Food and Drug Administration (FDA)-approved drugs, we predict that therapeutic drug classes, such as nervous system drugs, are more likely to be detected on the skin. Detecting drugs and other chemicals noninvasively on the skin using untargeted metabolomics could be a useful clinical advancement in therapeutic drug monitoring, adherence, and health status.
使用皮肤拭子和非靶向代谢组学分析,可以非侵入性地检测化学物质,包括一些全身给药的外源性化学物质及其生物转化产物。我们试图通过随机森林分类器来了解决定口服或全身给药的药物是否有可能在表皮上被观察到的主要驱动因素,从而预测哪些药物会在皮肤上被检测到。该分类器的训练使用了各种描述药物计算性质的分子描述符,例如体积、电负性、键能和电拓扑学等度量标准。预测表皮药物检测的受试者工作特征曲线下的平均面积为 0.71,并且使用 SHapley Additive exPlanations (SHAP) 模型解释技术来确定最相关的分子描述符。基于对 2561 种美国食品和药物管理局 (FDA) 批准药物的分析,我们预测治疗药物类别,如神经系统药物,更有可能在皮肤上被检测到。使用非靶向代谢组学技术非侵入性地检测皮肤中的药物和其他化学物质可能是治疗药物监测、依从性和健康状况方面的一项有用的临床进展。